Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LESSINA-21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved)
Prevention of pregnancy (FDA-approved)
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes first-pass metabolism in gut wall and liver. Levonorgestrel: metabolized via reduction and conjugation, partially involving CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98-99% (albumin and sex hormone-binding globulin, SHBG)
~99% bound to serum albumin and sex hormone-binding globulin.
2-4 L/kg (extensive distribution into tissues, reflecting lipophilicity and binding to steroid receptors)
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 88% (high bioavailability due to extensive absorption and minimal first-pass metabolism)
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe impairment; use with caution.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in acute hepatitis, severe decompensated cirrhosis (Child-Pugh C), or liver tumors. For mild (Child-Pugh A) to moderate (Child-Pugh B) impairment, use only if benefits outweigh risks; monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Use only after menarche. Same dosing as adults (0.1 mg/0.02 mg daily for 21 days) for adolescents aged 12-17 years. Safety and efficacy not established in premenarchal girls.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolic events and cardiovascular disease in women over 35 who smoke.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who smoke and use OCs should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction) - discontinue if signs occur,Increased risk of myocardial infarction and stroke, especially in smokers >35 years,Hepatic neoplasia (benign/malignant) - discontinue if jaundice or hepatic adenoma develops,Hypertension - monitor blood pressure; discontinue if hypertension develops,Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache - evaluate if new/worsening migraine,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (retinal thrombosis) - discontinue if unexplained vision loss,Depression - discontinue if severe,Reduce efficacy with certain drugs (e.g., anticonvulsants, antibiotics)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease (current or history),Known thrombophilic conditions (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Uncontrolled hypertension (BP ≥160/100 mm Hg),Diabetes with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura, age >35),Major surgery with prolonged immobilization,Known or suspected breast carcinoma or other estrogen-sensitive neoplasia,Hepatic adenoma or carcinoma, active liver disease, or impaired liver function,Undiagnosed abnormal uterine bleeding,Cigarette smoking in women >35 years,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice as they may increase ethinyl estradiol levels. No other significant food interactions. St. John's wort (herbal supplement) reduces contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is low. Second and third trimesters: no increased risk of major malformations; however, exposure may increase risk of neonatal jaundice, cholestasis, and transient hormonal effects. Discontinue if pregnancy is suspected.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk (M/P ratio not determined). May reduce milk production and composition. Use is generally not recommended during breastfeeding; alternative contraception should be considered.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Contraindicated in pregnancy; no dose adjustments are applicable. Discontinue use immediately if pregnancy is confirmed.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Lessina-21 is a low-dose combination oral contraceptive containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol. Administer on day 1 of menstrual period or first Sunday after onset. Use backup contraception for first 7 days if starting after day 5. Missed pill management: if one pill missed, take as soon as remembered; if two pills missed, take two pills on two consecutive days. CYP34A inducers (e.g., rifampin, St. John's wort) reduce efficacy; consider alternative contraception. Monitor for hypertension, thromboembolism, and migraine with aura. Eating grapefruit may increase ethinyl estradiol levels. Avoid in patients with migraine with aura, history of VTE, or breast cancer.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one pill at the same time every day. Do not skip pills.,Start your pack on the first day of your period or the first Sunday after your period starts.,If you miss one pill, take it as soon as you remember. If you miss two pills, take two pills for two days and use a backup method for 7 days.,Lessina-21 does not protect against STIs; use condoms.,Common side effects include nausea, headache, and breast tenderness; these often improve after 3 months.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.,Call your doctor if you have leg pain, chest pain, shortness of breath, or severe headaches.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LESSINA-21 vs AFIRMELLE, answered by our medical review team.
LESSINA-21 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LESSINA-21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LESSINA-21 is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LESSINA-21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LESSINA-21 is classified as Category C. FDA Pregnancy Category X. First trimester: oral contraceptive use is associated with a slight increase in cardiovascular defects and limb reduction defects, though absolute risk is. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.